Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
21 Results for "
mycolic
" in MedChemExpress (MCE) Product Catalog:
Products (21)
21 Results for "mycolic" in MCE Product Catalog:
Cat. No.: HY-N15643
CAS No.: 23040-84-8
Synonyms: α-MA (C80)
Category:
Target:
Research Areas:
Thiolactomycin is an orally active bacterial type II fatty acid synthase (FAS-II) inhibitor with antibacterial and antimalarial activities. Thiolactomycin specifically targets KasA/KasB in mycobacteria and FabB/FabF in bacteria, thereby inhibiting the biosynthesis of fatty acids and mycolic acids. Thiolactomycin can be used in studies related to tuberculosis, systemic bacterial infections, and experimental pyelonephritis .
Thiophene-2 (TP2) is a specific polyketide synthase 13 (Pks13) inhibitor. Thiophene-2 inhibits mycolic acid biosynthesis and rapidly leads to mycobacterial cell death. Thiophene-2 is active against Mycobacterium tuberculosis with a MIC value of 1 μM, and has potent anti-tuberculosis activity .
Cat. No.: HY-N15645
CAS No.: 2260795-20-6
Category:
Target:
NITD-916, a 4-hydroxy-2-pyridone derivative, is an orally active mycobacterial enoyl reductase InhA inhibitor with an IC50 of 570 nM. NITD-916 forms a ternary complex with InhA and NADH to block access to the fatty acyl substrate binding pocket. NITD-916 inhibition of InhA reduces the synthesis of mycolic acids and results in cell death. NITD-916 has potent anti-tuberculosis effects .
Cat. No.: HY-126564
CAS No.: 76808-16-7
Category:
Cat. No.: HY-N15644
CAS No.: 23599-54-4
Category:
Target:
Cat. No.: HY-W064918
CAS No.: 1473450-60-0
NITD-304 is an orally active anti-tuberculosis agent. NITD-304 exerts inhibitory and bactericidal activities gainst Mycobacterium tuberculosis and multidrug-resistant Mycobacterium tuberculosis. NITD-304 inhibits mycobacterial cell wall biosynthesis and demonstrates synergistic or additive growth inhibitory activity with select antibacterial agents. NITD-304 shows low risk of cardiotoxicity and drug-drug interactions, with no inhibition of major cytochrome P-450 enzymes or hERG channel. NITD-304 can be used for the research of tuberculosis and multidrug-resistant tuberculosis .
Cat. No.: HY-151806
CAS No.: 1097120-47-2
Target:
Research Areas:
HadAB-IN-1 is a potent HadAB inhibitor. HadAB-IN-1 inhibits HadAB enzyme complexes activity with an IC50 value of 0.03 μM. HadAB-IN-1 also affects mycolic acid biosynthesis in Mycobacterium tuberculosis (Mtb). HadAB-IN-1 can be used for the research of tuberculosis (TB) .
Cat. No.: HY-143473
CAS No.: 1051177-61-7
FabG1-IN-1 (Compound 29) is a potent MabA (FabG1) inhibitor with an IC50 of 38 µM .
Cat. No.: HY-173375
Mycobacterium Tuberculosis-IN-8 (Compound 6g) is a selective inhibitor of Mycobacterium tuberculosis (MTB) with an MIC value of 6.25 µg/mL against MTB H37Rv. Mycobacterium Tuberculosis-IN-8 shows potent antitubercular activities, inhibiting mycolic acid biosynthesis critical for bacterial cell wall integrity. Mycobacterium Tuberculosis-IN-8 is promising for research of antitubercular agents .
Cat. No.: HY-187335
Target:
Research Areas:
HadAB/InhA=IN-1 is a dual inhibitor of Mycobacterium tuberculosis InhA and HadAB with an InhA IC50 of 0.81 μM. HadAB/InhA=IN-1 inhibits InhA enzymatic activity in the FAS-II pathway of mycolic acid biosynthesis. HadAB/InhA=IN-1 undergoes EthA-mediated activation to covalently bind HadA and inhibit HadAB dehydratase function in the same FAS-II pathway. HadAB/InhA=IN-1 reduces mycolic acid-containing lipid and mycolic acid production, and accumulates standard fatty acids in Mycobacterium tuberculosis. HadAB/InhA=IN-1 exhibits antimycobacterial activity against drug-susceptible, ethA-deficient, and multi-drug-resistant Mycobacterium tuberculosis isolates. HadAB/InhA=IN-1 shows cytotoxic effects against human cancer and immortalized normal lung fibroblast cells. HadAB/InhA=IN-1 can be used for the research of tuberculosis .
Cat. No.: HY-181866
CAS No.: 2670430-25-6
Antibacterial agent 328 is a enoyl-ACP reductase (InhA) inhibitor and antimycobacterial agent. Antibacterial agent 328 blocks mycolic acid biosynthesis in Mycobacterium tuberculosis. Antibacterial agent 328 acts on both drug-resistant and drug-susceptible Mycobacterium tuberculosis strains. Antibacterial agent 328 exhibits favorable pharmacokinetic properties, drug-likeness, and a safety-related selectivity index. Antibacterial agent 328 can be used for research on tuberculosis .
Cat. No.: HY-170575
Pks13-IN-1 (Compound 44) is an orally active inhibitor for Mycobacterium tuberculosis Polyketide synthase 13 (Pks13). Pks13-IN-1 inhibits M. tuberculosis strain H37Rv with a MIC of 0.07 μM. Pks13-IN-1 exhibits antibacterial efficacy in mouse model .
Cat. No.: HY-179593
Target:
Research Areas:
GM47-1, a naphthalene scaffold derivative, is a potent mycolic acid transporter MmpL3 inhibitor exhibiting potent bactericidal activity against Mycobacterium abscessus (Mabs) with an MIC50 of 2.1 µM. GM47-1 targets MmpL3, disrupts cell wall integrity, and induces ATP leakage and uncouples respiration. GM47-1 can be used for Mycobacterium abscessus pulmonary disease (Mabs-PD) research .
Cat. No.: HY-180407
CAS No.: 1027102-50-6
UGM-IN-1 (compound 107) is a selective competitive inhibitor of Mycobacterium tuberculosis UDP-Galp mutase (UGM), encoded by Rv3809c. UGM-IN-1 inhibits the conversion of UDP-galactopyranose (UDP-Galp) to UDP-galactofuranose (UDP-Galf), thereby blocking the synthesis of key components of the mycobacterial cell wall, including mycolic acid-arabinogalactan (mAG) and liparabinomannan (LAM), leading to anti-mycobacterial activity against Mycobacterium tuberculosis. UGM-IN-1 is useful for research on tuberculosis, including drug-resistant tuberculosis .
Cat. No.: HY-181008
Target:
Research Areas:
Antitubercular agent-56, a Questiomycin A (HY-N8439) derivative, is a potent and orally active antitubercular agent. Antitubercular agent-56 disrupts mycobacterial envelope integrity by inhibiting FabD (Kd = 9.39 μM; IC50 = 49.60 μM). Antitubercular agent-56 exhibits good intracellular antimycobacterial activity against Mycobacterium tuberculosis (MTB) and drug-resistant MTB both in vitro and in vivo. Antitubercular agent-56 can be used for research on tuberculosis (TB) .
Cat. No.: HY-183968
BRD1554 is an inhibitor of the thioesterase domain of polyketide synthase 13 (Pks13) from Mycobacterium tuberculosis, and exhibits selective activity against Pks13-expressing strains. Pks13 is a polyketide synthase essential for the synthesis of branched-chain fatty acids in mycobacteria. BRD1554 serves as a scaffold molecule for anti-Mycobacterium tuberculosis agents. BRD1554 can be used in the research of tuberculosis .
Cat. No.: HY-181283
CAS No.: 2919699-59-3
MSU-43557 is a Mycobacterium abscessus MmpL3 (MAB_4508) inhibitor and bactericidal agent. MSU-43557 inhibits MmpL3 function, disrupts trehalose monomycolate synthesis, and reduces biofilm-associated Mycobacterium abscessus viability. MSU-43557 exerts bactericidal activity against intracellular Mycobacterium abscessus. MSU-43557 shows low eukaryotic cytotoxicity and low Mycobacterium abscessus resistance frequency. MSU-43557 can be used for the research of mycobacterium abscessus infection .
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
